{
  "Variants Include": [
    {
      "Gene": "PARK2",
      "variants": [
        {
          "HGVS": "NM_000385.3:c.992T>C",
          "cDNA Change": {
            "transcript": "NM_000385.3",
            "ref": "T",
            "alt": "C",
            "position": "992"
          },
          "Protein Change": {
            "ref": "C",
            "alt": "R",
            "position": "331"
          },
          "Description in input context": "Mutation of Cys331 to Arg in the RBR domain of Parkin"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's Disease",
    "MONDO": "MONDO:0005020"
  },
  "Experiment Method": [
    {
      "Assay Method": "In Vitro Ubiquitination Assay",
      "Material used": {
        "Material Source": "Recombinant Proteins",
        "Material Name": "Parkin and PACRG",
        "Description": "Recombinant Parkin and PACRG proteins were used to study their interaction and ubiquitination activity."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000385.3:c.992T>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Loss of interaction with PACRG and destabilization of Parkin",
          "Result Description": "The C331R mutation in Parkin disrupted its interaction with PACRG, leading to reduced stability and increased auto-ubiquitination."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the abstract."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the abstract."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type Parkin was used as a positive control for ubiquitination activity."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "No PACRG was used as a negative control to confirm the necessity of PACRG for Parkin stabilization."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "1"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Not explicitly described in the abstract."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Ubiquitination activity greater than 70% of wild-type.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Ubiquitination activity less than 30% of wild-type.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Co-localization Imaging",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293",
        "Description": "HEK293 cells were transfected with Parkin and PACRG to study their subcellular localization."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000385.3:c.992T>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Disruption of ER localization",
          "Result Description": "The C331R mutation in Parkin led to mislocalization from the ER, unlike wild-type Parkin which co-localized with PACRG in the ER."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the abstract."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the abstract."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type Parkin was used as a positive control for ER localization."
      },
      "Basic negative control": {
        "Basic negative控制": "Yes",
        "Description": "No PACRG was used as a negative control to confirm the role of PACRG in ER localization."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "1"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Not explicitly described in the abstract."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Co-localization with PACRG in ER greater than 80%.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Co-localization with PACRG in ER less than 20%.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}